MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

• Published in: Lung cancer (Auckland) Vol. 15; pp. 41 - 47
• Main Authors: Brazel, Danielle, Nagasaka, Misako
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2024; Dove; Dove Medical Press
• Subjects: bispecific antibody; Development and progression; Epidermal growth factor; epidermal growth factor receptor (egfr) mutations; first line treatment; Gene mutations; Lung cancer, Non-small cell; Pemetrexed; Tyrosine; bispecific antibody; epidermal growth factor receptor (EGFR) mutations; first line treatment
• ISSN: 1179-2728; 1179-2728
• DOI: 10.2147/LCTT.S453974

Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosine kinase inhibitor active against EGFR mutations including common resistance mutations. The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival. Here, we discuss the rationale for the study and the early results of MARIPOSA.